Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Richard Pratley MD
Richard E. Pratley MD Associate Editor
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
Silvio Inzucchi MD
Silvio E. Inzucchi MD Editor-in-Chief
See All Experts
featured
Published in Diabetes and
1 other channel

Journal Scan / Research · May 02, 2016

Cardiovascular Effects of SGLT-2 Inhibitors in Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Camille Powe MD

The Lancet Diabetes & Endocrinology
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiovascular Events, Death, and Major Safety Outcomes in Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis
Lancet Diabetes Endocrinol 2016 May 01;4(5)411-419, JH Wu, C Foote, J Blomster, T Toyama, V Perkovic, J Sundström, B Neal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated